Product Information for Benacort Hayfever Relief for Adults 64 micrograms, Nasal Spray, Benacort 64 micrograms Nasal Spray, Benadryl Allergy Relief, Benadryl Allergy Relief Plus Decongestant Capsules, Benadryl One A Day Relief/Benadryl Allergy One A Day 10mg Tablets, Benadryl Allergy Liquid Release 10mg Capsules, Benadryl Allergy Children's 6+ 1mg/ml Oral Solution, Benadryl Allergy Children's 6+ 1mg/ml Oral Solution 60ml, Benadryl Allergy Children's 1mg/mL Oral Solution, Benadryl Allergy Children's 1mg/mL Oral Solution 120ml

Adverse events should be reported. Reporting forms and information can be found at at https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to McNeil Products Limited on 0808 238 9999.

Benacort Hayfever Relief for Adults 64 Micrograms Nasal Spray (Budesonide) Product Information

Presentation:
Nasal spray, suspension. Each actuation contains 64mcg budesonide
Uses:
Treatment of seasonal allergic rhinitis (hay fever).
Dosage *(adults)**:***
Initially: Two sprays (128mcg) into each nostril in the morning. Once symptoms are under control, use a maintenance dose of one spray (64 micrograms) into each nostril each morning. No more than four sprays in one day. Full effect not achieved until after a few days treatment. If symptoms are not controlled, or persist for longer than 7 days of treatment, medical advice must be sought. Benacort should not be used continuously for longer than 1 month without medical advice.
Paediatric population: not to be used in children and adolescents under 18 years of age.
Contraindications
Hypersensitivity to active ingredient or to any of the excipients, and patients taking HIV medications. See the SmPC for further details.
Warnings and precautions:
Patients should consult a physician before use if: they are using a corticosteroid for other conditions, they currently have or have been exposed to tuberculosis, chicken pox or measles, they have fungal or viral infections of the airways, they have severe or frequent nose bleeds or have/had nose ulcers, nose surgery or injury, they have ever been diagnosed with glaucoma or cataracts, they have an eye infection or diabetes. Patients should consult a pharmacist or doctor if they develop signs or symptoms of an infection, such as persistent fever, while taking this medicine. Reduced liver function affects the elimination of corticosteroids, may lead to higher systemic exposure and possible

systemic side effects. Systemic effects of nasal corticosteroids may occur, particularly at high doses used for prolonged periods. Co-treatment with CYP3A inhibitors including cobicistat-containing products is expected to increase the risk of systemic side effects. In cases of clinically significant adrenal suppression, additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. Raised plasma concentrations and enhanced effects of corticosteroids have been observed in women treated with oestrogens and contraceptive steroids, but no effect has been observed during concomitant intake of low dose combination oral contraceptives. As adrenal function may be suppressed this may lead to false results in ACTH stimulation test for diagnosing pituitary insufficiency. See the SmPC (summary of product characteristics) for full details. Contains potassium sorbate (E202) which may cause local skin reactions, (e.g. contact dermatitis).

Pregnancy and lactation:

Avoid during pregnancy unless benefit outweighs risk. No effects on breast fed child are expected at therapeutic doses. This medicine should not be used during pregnancy or breast-feeding without first consulting a doctor or pharmacist.

Side effects: *Consult SmPC for full list of side effects*

Common: haemorrhagic secretion, epistaxis, nasal discomfort (sneezing, stinging and dryness).

Uncommon: immediate and delayed hypersensitivity reactions including erythema, urticaria, rash, dermatitis, angioedema and pruritus, muscle spasms.

Rare: anaphylactic reaction, signs and symptoms of systemic corticosteroid effects, including adrenal suppression and growth retardation, nasal septum perforation, nasal ulcer and dysphonia, blurred vision, contusion.

Very rare: ulceration of mucous membrane.

Not known: raised intraocular pressure or glaucoma, cataract.

In rare cases, signs or symptoms of glucocorticosteroid-side effects such as Cushing's syndrome, Cushingoid features, psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) may occur. Acute overdose even in excessive doses, is not expected to be a clinical problem.

RRP (excl. VAT): 60 actuations: £6.99.

Legal category: GSL

PL holder: McNeil Products Ltd, 50 – 100 Holmers Farm, Way High Wycombe, Buckinghamshire HP12 4EG

PL number: 15513/0409

Date of preparation: 28 March 2023

Benacort 64 Micrograms Nasal Spray (Budesonide) Product Information

Presentation:

Nasal spray, suspension. Each actuation contains 64mcg budesonide

Uses:

Prevention and treatment of seasonal allergic rhinitis (hay fever).

***Dosage** (adults):*

Once daily dosing: 128mcg into each nostril in the morning. Twice daily dosing: 64mcg into each nostril morning and evening. If good effect is achieved, 64 micrograms into each nostril each morning. Full effect not achieved until after a few days treatment. Treatment of seasonal rhinitis should start, if possible, before exposure to the allergens.

If symptoms are not controlled, or persist for longer than 2 weeks of treatment, medical advice must be sought. Benacort should not be used continuously for longer than 3 months.
Paediatric population*:* not to be used in children and adolescents under 18 years of age.

Contraindications

Hypersensitivity to active ingredient or to any of the excipients.

Warnings and precautions:

If symptoms are not controlled or persist for longer than 2 weeks of treatment, medical advice must be sought. Patients should consult a physician before use if: they are using a corticosteroid for other conditions, they currently have or have been exposed to tuberculosis, chicken pox or measles, they have severe or frequent nosebleed or have/had nose ulcers, nose surgery or injury, they have ever been diagnosed with glaucoma or cataracts, they have an eye infection or diabetes. Special care needed: when treating patients transferred from oral steroids, where disturbances of hypothalamic-pituitary-adrenal (HPA) axis could be expected; in patients with fungal and viral infections of the airways. Reduced liver function affects the elimination of corticosteroids, may lead to higher systemic exposure and possible systemic side effects. Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. CYP3A inhibitors may increase systemic exposure to budesonide. Raised plasma concentrations and enhanced effects of corticosteroids have been observed in women treated with oestrogens and contraceptive steroids. No effect observed during concomitant intake of low dose oral contraceptives. As adrenal function may be suppressed this may lead to false results in ACTH stimulation test for diagnosing pituitary insufficiency. Contains potassium sorbate (E202) which may cause local skin reactions, (e.g. contact dermatitis).

Pregnancy and lactation:

Avoid during pregnancy unless benefit outweighs risk. No effects on breast fed child are expected at therapeutic doses.

Side effects: *Consult SmPC for full list of side effects*

Common: haemorrhagic secretion and epistaxis, nasal Irritation (sneezing, stinging and dryness).

Uncommon: immediate and delayed hypersensitivity reactions including erythema, urticaria, rash, dermatitis, angioedema and pruritus, muscle spasms.

Rare: anaphylactic reaction, signs and symptoms of systemic corticosteroid effects, including adrenal suppression and growth retardation, nasal septum perforation, nasal ulcer and dysphonia, blurred vision, contusion.

Very rare: ulceration of mucous membrane.

Not known: raised intraocular pressure or glaucoma and cataract.

In rare cases, signs or symptoms of glucocorticosteroid-side effects such as Cushing's syndrome, Cushingoid features, psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) may occur. Acute overdose even in excessive doses, is not expected to be a clinical problem.

RRP (excl. VAT): 120 actuations: £9.16

Legal category: P

PL holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire HP12 4EG, UK

PL number: 15513/0404

Date of preparation: 28 March 2023.

Benadryl Allergy Relief (Acrivastine) Product Information

Presentation:
Acrivastine 8 mg capsules.
Uses:
Symptomatic relief of allergic rhinitis. Also chronic idiopathic urticaria.
Dosage:
Adults and children aged 12 – 65 years: One capsule up to 3 times a day.
Contraindications:
Hypersensitivity to acrivastine or triprolidine or any excipients listed in section 6.1 of the SPC. Severe renal impairment. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
Precautions:
Concomitant administration of acrivastine with CNS depressants may produce additional impairment in mental alertness in some individuals. Patients with renal impairment should consult with a physician before use.
This product may cause drowsiness. Acrivastine may cause dizziness and somnolence- caution when engaging in activities which require mental alertness until familiar with response to drug. Caution when taking with ketoconazole, erythromycin or grapefruit juice.
Pregnancy and Lactation:
Not recommended
Side effects:
Very common: somnolence.
Common: dry mouth, dizziness
Unknown: hypersensitivity (including dyspnoea and face swelling), rash.
RRP (ex VAT): 12s £5.24, 24s £8.62, 48s: £15.41
Legal category: 12s GSL, 24s GSL, 48s P
PL Holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK
PL Number: 12s & 24s 15513/0128, 48s 15513/0035
Date of prep: 07/12/2020

Benadryl Allergy Relief Plus Decongestant Capsules (Acrivastine and Pseudoephedrine Hydrochloride) Product Information

Presentation:
Acrivastine 8mg and pseudoephedrine hydrochloride 60mg capsules.
Uses:
Symptomatic relief of allergic rhinitis.
Dosage:
Adults and children 12 to 65 years: one capsule as necessary, up to three times a day.
Contraindications:
This product is not for use in children under 12 years of age and in the elderly. It is also contraindicated in individuals with known hypersensitivity to acrivastine, pseudoephedrine hydrochloride, or to any of its excipients; cardiovascular disease including hypertension, diabetes mellitus, phaeochromocytoma, hyperthyroidism, closed angle glaucoma, severe acute or chronic kidney disease/renal failure. This product is also contraindicated in individuals with concomitant use of other sympathomimetic

decongestants, beta-blockers, or monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOI treatment. The concomitant use of MAOIs may cause a rise in blood pressure and/or hypertensive crisis.

Precautions:

This product contains lactose monohydrate; patients with hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Caution should be exercised when using the product in the presence of severe hepatic impairment or moderate to severe renal impairment and in occlusive vascular disease. Patients with difficulty in urination and/or enlargement of the prostate, or patients with thyroid disease who are receiving thyroid hormones, or patients with decreased kidney function should not take pseudoephedrine-containing products unless directed by a physician. This product should be discontinued if hallucinations, restlessness, or sleep disturbances occur.
Pseudoephedrine has known interactions with the following medicinal products: moclobemide, antihypertensives such as bretylium, betanidine, guanethidine, debrisoquine, methyldopa, adrenergic neurone blockers and beta blockers, cardiac glycosides, ergotamine and methysergide, appetite suppressants and amphetamine-like psychostimulants, oxytocin, tricyclic antidepressants, or halogenated anaesthetic agents. There are no data to demonstrate an interaction between acrivastine and ketoconazole, erythromycin, or grapefruit juice. However, due to known interactions between these compounds and other non-sedating antihistamines, caution is advised. It may also enhance the sedative effects of central nervous system depressants, including alcohol, sedatives, and tranquilisers.
Severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with pseudoephedrine-containing products. If signs and symptoms such as pyrexia, erythema, or many small pustules are observed, administration of this medicine should be discontinued, and appropriate measures taken if needed.
Some cases of ischaemic colitis have been reported with pseudoephedrine. This product should be discontinued, and medical advice sought if sudden abdominal pain, rectal bleeding, or other symptoms of ischaemic colitis develop.
Cases of ischaemic optic neuropathy have been reported with pseudoephedrine. This product should be discontinued if sudden loss of vision or decreased visual acuity such as scotoma occurs.
Cases of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) have been reported with the use of pseudoephedrine-containing products. The risk is increased in patients with severe or uncontrolled hypertension, or with severe acute or chronic kidney disease/renal failure. Pseudoephedrine should be discontinued, and immediate medical assistance sought if the following symptoms occur: sudden severe headache or thunderclap headache, nausea, vomiting, confusion, seizures and/or visual disturbances.
This medicine contains less than 1 mmol sodium (23mg) per dose, that is to say essentially ‘sodium-free’.
Please refer to Summary of Product Characteristics for detailed information.

Pregnancy & lactation:

This product should not be used during pregnancy or lactation unless the potential benefit of treatment to the mother outweighs the possible risks to the developing foetus or nursing infant.

Side effects:

Very Common: headache, somnolence
Common: insomnia, nervousness, dizziness, dry mouth, nausea

Not Known: hypersensitivity (including dyspnoea and facial swelling), cross-sensitivity with other sympathomimetics, anxiety, euphoric mood, excitability, hallucinations, irritability, paranoid delusions, restlessness, sleep disorder, cerebrovascular accident, paraesthesia, posterior reversible encephalopathy syndrome (PRES), reversible cerebral vasoconstriction syndrome (RCVS), psychomotor hyperactivity, tremor, ischaemic optic neuropathy, dysrhythmias, myocardial infarction/myocardial ischaemia, palpitations, tachycardia, hypertension, ischaemic colitis, vomiting, angioedema, pruritus, rash, severe skin reactions including acute generalised exanthematous pustulosis (AGEP), dysuria, urinary retention (in men in whom prostatic enlargement could have been an important predisposing factor)
Please refer to Summary of Product Characteristics for detailed information.
RRP (ex-VAT): 12s £5.82
Legal cat: P
PL holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK
PL no: 15513/0017
Date of prep: 29 May 2024

Benadryl One A Day Relief / Benadryl Allergy One A Day 10mg Tablets (Cetirizine Dihydrochloride) Product Information

Presentation:
Cetirizine dihydrochloride 10mg film-coated tablets with breakline and Y-Y logo.
Excipients with known effect: lactose monohydrate.
Uses:
Symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
Dosage:
12 years and above: 10mg once daily.
Contraindications:
Hypersensitivity to ingredients, hydroxyzine or piperazine derivatives; severe renal impairment, galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
Precautions:
Renal impairment: dosage adjustment required – refer to SPC. Caution with concomitant alcohol consumption, in epilepsy and those at risk of convulsions. Caution in patients with predisposition factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia). Do not drive or operate machinery until familiar with response to drug. Severe skin reactions such as acute generalised exanthematous pustulosis (AGEP) have been reported very rarely with cetirizine-containing products – refer to SPC.
Fertility, Pregnancy and Lactation:
Caution should be exercised when prescribing to pregnant or lactating women.
Side effects:
Common: Somnolence, fatigue, dizziness, headache, abdominal pain, dry mouth, nausea, pharyngitis, rhinitis.
Uncommon: agitation, paraesthesia, diarrhoea, pruritus, rash, asthenia, malaise. *Rare:* Hypersensitivity, aggression, confusion, depression, hallucination, insomnia, convulsions, tachycardia, hepatic function abnormal, urticaria, oedema, weight increased.

Very rare: thrombocytopenia, anaphylactic shock, tics, dysgeusia, syncope, tremor, dystonia, dyskinesia, accommodation disorder, blurred vision, oculogyration, angioneurotic oedema, dysuria, enuresis, fixed drug eruption. *Not known:* increased appetite, suicidal ideation, amnesia, memory impairment, eye pain, vertigo, urinary retention, erectile dysfunction, acute generalised exanthematous pustulosis (AGEP), arthralgia, pruritus upon withdrawal, hepatitis.
RRP (ex-VAT)/NHS Cost: 7s £5.13; 14s £6.83; 30s £8.33.
Legal category: GSL.
PL Holder: McNeil Products Limited, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG.
PL Number(s): 15513/0118.
Date of prep: 16 Nov 2023

Benadryl Allergy Liquid Release 10mg Capsules (Cetirizine Dihydrochloride) Product Information

Presentation:
Soft capsules containing 10mg cetirizine dihydrochloride.
Uses:
For the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Also for the relief of symptoms of chronic idiopathic urticaria.
Dosage:
12 years and above: 10mg once daily. Under 12 years: Not recommended.
Contraindications:
Hypersensitivity to cetirizine, hydroxyzine or any piperazine derivatives, to soya, peanut, or to any of the excipients listed in section 6.1 of the SPC. Moderate to severe renal impairment.
Precautions:
Caution with concomitant alcohol consumption. Patients with both liver and kidney disease should consult a physician before use. Caution in epilepsy patients andthose at risk of convulsions. Caution in patients with predisposition factors of urinary retention. Allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them. Pruritus and/or urticaria may occur when cetirizine is stopped, even if those symptoms were not present before treatment initiation.
Pregnancy and Lactation:
Consult a physician before use.
Side effects:
Common: Somnolence, fatigue, dizziness, headache, abdominal pain, dry mouth, nausea, pharyngitis, diarrhoea, rhinitis.
Uncommon: agitation, paraesthesia, diarrhoea, pruritus, rash, asthenia, malaise.
Rare: Hypersensitivity, aggression, confusion, depression, hallucination, insomnia, convulsions, tachycardia, hepatic function abnormal, urticaria, oedema, weight increased.
Very rare: thrombocytopenia, anaphylactic shock, tics, dysgeusia, dystonia, dyskinesia, angioneurotic oedema, fixed drug eruption, syncope, tremor, accommodation disorder, blurred vision, oculogyration, eye swelling, cough, dysuria, enuresis.
Not known: increased appetite, suicidal ideation, amnesia, memory impairment,

vertigo, urinary retention, eye pain, erectile dysfunction, nightmares, hepatitis, acute generalised exanthematous pustulosis (AGEP), arthralgia, pruritus upon withdrawal. Consult SPC for additional side effects.
RRP (ex VAT): 7s £4.41
Legal category: GSL
PL Holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK.
PL Number: 15513/0378
Date of prep: 18 Aug 2023

Benadryl Allergy Children's 6+ 1mg/ml Oral Solution (Cetirizine Dihydrochloride) Product Information

Presentation:
Clear and colourless liquid.
Uses:
Symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
Dosage:
6 to 12 years: 5ml twice daily; *12 years and above:* 10ml once daily.
Contraindications:
Hypersensitivity to cetirizine, hydroxyzine or piperazine derivatives or any of the excipients, severe renal impairment, hereditary fructose intolerance.
Precautions:
Renal impairment: dosage adjustment required - refer to SPC. Caution with concomitant alcohol consumption, in epilepsy and those at risk of convulsions, in patients with predisposing factors of urinary retention. Do not drive or operate machinery until familiar with response to drug. Wash-out period of 3 days is recommended before performing an allergy skin test. Contains benzyl alcohol which may cause allergic reactions.
Pregnancy and Lactation:
On healthcare professional advice only.
Side effects:
Common: somnolence, fatigue, dizziness, headache, abdominal pain, dry mouth, nausea, pharyngitis, diarrhoea, rhinitis.
Uncommon: agitation, paraesthesia, diarrhoea, pruritus, rash, asthenia, malaise.
Rare: hypersensitivity, aggression, confusion, depression, hallucination, insomnia, convulsions, movement disorders, tachycardia, hepatic function abnormal, urticaria, oedema, weight increased.
Very rare: thrombocytopenia, anaphylactic shock, tics, dysgeusia, dystonia, dyskinesia, angioneurotic oedema, fixed drug eruption, syncope, tremor, accommodation disorder, blurred vision, oculogyration, eye swelling, cough, dysuria, enuresis, feeling abnormal, nausea.
Not known: increased appetite, suicidal ideation, amnesia, memory impairment, vertigo, urinary retention, eye pain, erectile dysfunction, nightmares, acute generalised exanthematous pustulosis (AGEP), arthralgia, pruritus upon withdrawal, hepatitis.
RRP (ex VAT): 70ml £4.83
Legal category: GSL
PL Holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire HP12 4EG, UK.

PL Number: PL 15513/0124
Date of prep: 18 August 2023

Benadryl Allergy Children's 6+ 1mg/ml Oral Solution (Cetirizine Dihydrochloride) 60ml Product Information

Presentation:
Clear and colourless liquid.

Uses:
Symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

Dosage:
6 to 12 years: 5ml twice daily; *12 years and above:* 10ml once daily.

Contraindications:
Hypersensitivity to cetirizine, hydroxyzine or piperazine derivatives or any of the excipients, severe renal impairment, hereditary fructose intolerance.

Precautions:
Renal impairment: dosage adjustment required - refer to SPC. Caution with concomitant alcohol consumption, in epilepsy and those at risk of convulsions, in patients with predisposing factors of urinary retention. Do not drive or operate machinery until familiar with response to drug. Wash-out period of 3 days is recommended before performing an allergy skin test. Contains benzyl alcohol which may cause allergic reactions.

Pregnancy and Lactation:
On healthcare professional advice only.

Side effects:
Common: Somnolence, fatigue, dizziness, headache, abdominal pain, dry mouth, nausea, pharyngitis, diarrhoea, rhinitis.
Uncommon: agitation, paraesthesia, diarrhoea, pruritus, rash, asthenia, malaise.
Rare: Hypersensitivity, aggression, confusion, depression, hallucination, insomnia, convulsions, movement disorders, tachycardia, hepatic function abnormal, urticaria, oedema, weight increased.
Very rare: thrombocytopenia, anaphylactic shock, tics, dysgeusia, dystonia, dyskinesia, angioneurotic oedema, fixed drug eruption, syncope, tremor, accommodation disorder, blurred vision, oculogyration, eye swelling, cough, dysuria, enuresis, feeling abnormal, nausea.
Not known: increased appetite, suicidal ideation, amnesia, memory impairment, vertigo, urinary retention, eye pain, erectile dysfunction, nightmares, acute generalised exanthematous pustulosis (AGEP), arthralgia, pruritus upon withdrawal, hepatitis.
RRP (ex VAT): 60ml £4.83

Legal category: GSL
PL Holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire HP12 4EG, UK.
PL Number: PL 15513/0124
Date of prep: 09 August 2023

Benadryl Allergy Children's 1mg/mL Oral Solution (Cetirizine Dihydrochloride) Product Information

Presentation:
Clear and colourless liquid.
Uses:
Symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
Dosage:
2 to 6 years: 2.5mL twice daily; *6 to 12 years:* 5mL twice daily; *12 years and above:* 10ml once daily.
Contraindications:
Hypersensitivity to cetirizine, hydroxyzine or piperazine derivatives or any of the excipients, severe renal impairment, hereditary fructose intolerance.
Precautions:
Renal impairment: dosage adjustment required - refer to SPC. Caution with concomitant alcohol consumption, in epilepsy and those at risk of convulsions, in patients with predisposing factors of urinary retention. Do not drive or operate machinery until familiar with response to drug. Wash-out period of 3 days is recommended before performing an allergy skin test. Contains benzyl alcohol which may cause allergic reactions.
Pregnancy and Lactation: On healthcare professional advice only.
Side effects:
Common: somnolence, fatigue, dizziness, headache, abdominal pain, dry mouth, nausea, pharyngitis, diarrhoea, rhinitis.
Uncommon: agitation, paraesthesia, diarrhoea, pruritus, rash, asthenia, malaise.
Rare: hypersensitivity, aggression, confusion, depression, hallucination, insomnia, convulsions, movement disorders, tachycardia, hepatic function abnormal, urticaria, oedema, weight increased.
Very rare: thrombocytopenia, anaphylactic shock, tics, dysgeusia, dystonia, dyskinesia, angioneurotic oedema, fixed drug eruption, syncope, tremor, accommodation disorder, blurred vision, oculogyration, eye swelling, cough, dysuria, enuresis, feeling abnormal, nausea.
Not known: increased appetite, suicidal ideation, amnesia, memory impairment, vertigo, urinary retention, eye pain, erectile dysfunction, nightmares, acute generalised exanthematous pustulosis (AGEP), arthralgia, pruritus upon withdrawal, hepatitis.
RRP (ex VAT): 100ml, £5.41
Legal category: P
PL Holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe Buckinghamshire, HP12, 4EG UK.
PL Number: PL 15513/0138
Date of prep: 18 August 2023

Benadryl Allergy Children's 1mg/mL Oral Solution (Cetirizine Dihydrochloride) 120ml Product Information

Presentation:
Clear and colourless liquid.

Uses:

Symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.

Dosage:
2 to 6 years: 2.5ml twice daily; *6 to 12 years:* 5ml twice daily; *12 years and above:* 10ml once daily.

Contraindications:
Hypersensitivity to cetirizine, hydroxyzine or piperazine derivatives or any of the excipients, severe renal impairment, hereditary fructose intolerance.

Precautions:
Renal impairment: dosage adjustment required - refer to SPC. Caution with concomitant alcohol consumption, in epilepsy and those at risk of convulsions, in patients with predisposing factors of urinary retention. Do not drive or operate machinery until familiar with response to drug. Wash-out period of 3 days is recommended before performing an allergy skin test. Contains benzyl alcohol which may cause allergic reactions.
Pregnancy and Lactation: On healthcare professional advice only.

Side effects:
Common: Somnolence, fatigue, dizziness, headache, abdominal pain, dry mouth, nausea, pharyngitis, diarrhoea, rhinitis.
Uncommon: agitation, paraesthesia, diarrhoea, pruritus, rash, asthenia, malaise.
Rare: Hypersensitivity, aggression, confusion, depression, hallucination, insomnia, convulsions, movement disorders,
tachycardia, hepatic function abnormal, urticaria, oedema, weight increased.
Very rare: thrombocytopenia, anaphylactic shock, tics, dysgeusia, dystonia, dyskinesia, angioneurotic oedema, fixed drug eruption, syncope, tremor, accommodation disorder, blurred vision, oculogyration, eye swelling, cough, dysuria, enuresis, feeling abnormal, nausea.
Not known: increased appetite, suicidal ideation, amnesia, memory impairment, vertigo, urinary retention, eye pain, erectile dysfunction, nightmares, acute generalised exanthematous pustulosis (AGEP), arthralgia, pruritus upon withdrawal, hepatitis.
RRP (ex VAT): 120ml £5.41

Legal category: P
PL Holder: McNeil Products Ltd, 50 – 100 Holmers Farm Way, High Wycombe Buckinghamshire, HP12, 4EG UK
PL Number: PL 15513/0138
Date of prep: 09 August 2023